Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Comparator TIV Clear all
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

How Healthy Adults Respond to the Nasal Flu Vaccine

NCT07726862
View directory record Official record
Conditions
Mucosal Immune Response to Influenza Vaccination
Interventions
FluMist (Live Attenuated Influenza Vaccine)
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 16, 2026, 9:40 AM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.

NCT01224795
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Placebo Comparator
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
96
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 93 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 16, 2026, 9:40 AM EDT
Not yet recruiting Not applicable Interventional

Clinical Validation of the Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings

NCT07217639
View directory record Official record
Conditions
COVID -19, Influenza A, Influenza B, Respiratory Synctial Virus, RSV, Rhinovirus
Interventions
Aptitude Medical Systems Respiratory Panel Test
Diagnostic Test
Lead sponsor
Aptitude Medical Systems
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Trussville, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

NCT05333289
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1030, mRNA-1020, mRNA-1010, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
15
States / cities
Phoenix, Arizona • Coral Gables, Florida • Jupiter, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults

NCT05755620
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Quadrivalent Inactivated Vaccine, Sodium Chloride, 0.9%, VRC-FLUNPF099-00-VP (H1ssF_3928)
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine in a Pediatric Population

NCT00959049
View directory record Official record
Conditions
Influenza
Interventions
CSL's Influenza Virus Vaccine (Afluria), Influenza Virus Vaccine (Fluzone)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 17 Years
Enrollment
1,474 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
23
States / cities
Chandler, Arizona • Harrisburg, Arkansas • Jonesboro, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

NCT02307851
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent VLP Vaccine, Comparator TIV
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
5
States / cities
Anaheim, California • Miami, Florida • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

NCT03739112
View directory record Official record
Conditions
Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Interventions
Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine
Biological
Lead sponsor
Medicago
Industry
Eligibility
65 Years and older
Enrollment
12,794 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
50
States / cities
Mobile, Alabama • Tempe, Arizona • Banning, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

NCT02242643
View directory record Official record
Conditions
Influenza
Interventions
FluLaval™ Quadrivalent, Fluzone® Quadrivalent
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
2,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
64
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Assess the Immunogenicity and Safety of an Investigational Influenza Vaccine in Children

NCT00980005
View directory record Official record
Conditions
Influenza
Interventions
GSK investigational vaccine GSK1557482A, Fluzone®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
3 Years to 17 Years
Enrollment
2,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
28
States / cities
Birmingham, Alabama • Benton, Arkansas • Huntington Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Not applicable Interventional Results available

SARS-CoV-2 and Influenza A/B in Point-of-Care and Non-Laboratory Settings

NCT06191393
View directory record Official record
Conditions
SARS-CoV-2 Infection, Influenza A, Influenza B
Interventions
Aptitude Medical Systems Metrix COVID/Flu Test
Diagnostic Test
Lead sponsor
Aptitude Medical Systems
Industry
Eligibility
2 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Trussville, Alabama • Goleta, California • Chelmsford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults

NCT05945485
View directory record Official record
Conditions
Influenza
Interventions
DCVC H1 HA mRNA vaccine, Quadrivalent Recombinant Seasonal Influenza Vaccine, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Dose-Finding Study of Favipiravir in the Treatment of Uncomplicated Influenza

NCT01068912
View directory record Official record
Conditions
Influenza
Interventions
Favipiravir, Placebo comparator
Drug
Lead sponsor
MDVI, LLC
Industry
Eligibility
20 Years to 80 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
148
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 118 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children

NCT00764790
View directory record Official record
Conditions
Influenza
Interventions
Fluarix, Fluzone
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
3,317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

NCT06602531
View directory record Official record
Conditions
Influenza, Human
Interventions
ARCT-2304, Control vaccine younger adults, Control vaccine older adults, Placebo Vaccine
Biological · Other
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
La Mesa, California • San Bernardino, California • Longmont, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 16, 2026, 9:40 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

NCT05044195
View directory record Official record
Conditions
Influenza, Human
Interventions
aQIV, Comparator QIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
50 Years to 64 Years
Enrollment
2,044 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Mobile, Alabama • Tempe, Arizona • Atlantis, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 16, 2026, 9:40 AM EDT